Cargando…

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32

BACKGROUND: BM32 is a grass pollen allergy vaccine based on recombinant fusion proteins consisting of nonallergenic peptides from the IgE-binding sites of the 4 major grass pollen allergens and the hepatitis B preS protein. OBJECTIVE: We sought to study the safety and clinical efficacy of immunother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niederberger, Verena, Neubauer, Angela, Gevaert, Philippe, Zidarn, Mihaela, Worm, Margitta, Aberer, Werner, Malling, Hans Jørgen, Pfaar, Oliver, Klimek, Ludger, Pfützner, Wolfgang, Ring, Johannes, Darsow, Ulf, Novak, Natalija, van Wijk, Roy Gerth, Eckl-Dorna, Julia, Focke-Tejkl, Margarete, Weber, Milena, Müller, Hans-Helge, Klinger, Joachim, Stolz, Frank, Breit, Nora, Henning, Rainer, Valenta, Rudolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392176/ https://www.ncbi.nlm.nih.gov/pubmed/29361332 http://dx.doi.org/10.1016/j.jaci.2017.09.052

Ejemplares similares

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG(4) response
por: Eckl-Dorna, Julia, et al.
Publicado: (2019)

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines
por: Weber, Milena, et al.
Publicado: (2017)

Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy
por: Marth, Katharina, et al.
Publicado: (2014)

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy
por: Focke-Tejkl, Margarete, et al.
Publicado: (2015)

Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future
por: Valenta, Rudolf, et al.
Publicado: (2016)

Poor association of allergen‐specific antibody, T‐ and B‐cell responses revealed with recombinant allergens and a CFSE dilution‐based assay
por: Eckl‐Dorna, J., et al.
Publicado: (2015)

Critical and direct involvement of the CD23 stalk region in IgE binding
por: Selb, Regina, et al.
Publicado: (2016)

Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32
por: Tulaeva, Inna, et al.
Publicado: (2020)

Characterisation and culture of primary human nasal epithelial cells and the influence of Interferon-gamma
por: Waltl, Eva, et al.
Publicado: (2014)

Clinical endpoints in allergen immunotherapy: State of the art 2022
por: Gerth van Wijk, Roy, et al.
Publicado: (2023)

Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1
por: Akinfenwa, Oluwatoyin, et al.
Publicado: (2021)

Establishment of a cell culture model based on primary epithelial cells to investigate damage and repair of respiratory epithelial cells
por: Waltl, Eva E, et al.
Publicado: (2015)

Recombinant allergen-based provocation testing()
por: Niederberger, Verena, et al.
Publicado: (2014)

Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response
por: Borochova, Kristina, et al.
Publicado: (2021)

Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy
por: Freidl, Raphaela, et al.
Publicado: (2016)

Resistance of parvalbumin to gastrointestinal digestion is required for profound and long‐lasting prophylactic oral tolerance
por: Freidl, Raphaela, et al.
Publicado: (2019)

Trimolecular complex between major birch pollen allergen, Bet v 1, monoclonal allergen-specific human IgE and recombinant CD23
por: Selb, Regina, et al.
Publicado: (2014)

Primary Nasal Epithelial Cells From Allergic and Non-allergic Individuals Show Comparable Barrier Function
por: Waltl, Eva E., et al.
Publicado: (2019)

Antibodies induced by immunization with a hypoallergenic mutant of the major fish allergen Cyp c 1 inhibit allergic symptoms in a mouse model of fish allergy
por: Gstoettner, AC, et al.
Publicado: (2013)

Tracing antigen signatures in the human IgE repertoire
por: Marth, Katharina, et al.
Publicado: (2010)

A B Cell Epitope Peptide Derived from the Major Grass Pollen Allergen Phl p 1 Boosts Allergen-Specific Secondary Antibody Responses without Allergen-Specific T Cell Help
por: Narayanan, Meena, et al.
Publicado: (2017)

Expression and characterization of recombinant Par j 1 and Par j 2 resembling the allergenic epitopes of Parietaria judaica pollen
por: Dorofeeva, Yulia, et al.
Publicado: (2019)

Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future?
por: Valenta, Rudolf, et al.
Publicado: (2018)

Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers
por: Madritsch, Christoph, et al.
Publicado: (2015)

Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials?
por: Pfaar, Oliver, et al.
Publicado: (2015)

Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses
por: Eckl-Dorna, Julia, et al.
Publicado: (2019)

Characterisation of recombinant CD23 in the trimeric complex with IgE and allergen
por: Selb, Regina Maria, et al.
Publicado: (2015)

Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy
por: Zieglmayer, Petra, et al.
Publicado: (2016)

Biochemical, Biophysical and IgE-Epitope Characterization of the Wheat Food Allergen, Tri a 37
por: Pahr, Sandra, et al.
Publicado: (2014)

Features of the Human Antibody Response against the Respiratory Syncytial Virus Surface Glycoprotein G
por: Borochova, Kristina, et al.
Publicado: (2020)

AIT und Covid-19 - Empfehlung von DGAKI und AeDA
por: Worm, Margitta, et al.
Publicado: (2020)

Allergen Microarray Indicates Pooideae Sensitization in Brazilian Grass Pollen Allergic Patients
por: Moreira, Priscila Ferreira de Sousa, et al.
Publicado: (2015)

Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy
por: Linhart, B, et al.
Publicado: (2014)

Antibody Conjugates Bispecific for Pollen Allergens and ICAM-1 with Potential to Prevent Epithelial Allergen Transmigration and Rhinovirus Infection
por: Weichwald, Christina, et al.
Publicado: (2023)

Subcutaneous birch pollen allergen immunotherapy with a depigmented polymerized extract shows only sustained and long‐term efficacy in a subgroup of monosensitized adults and adolescents with allergic rhinitis
por: Novak, Natalija, et al.
Publicado: (2022)

Comparison of the Specificities of IgG, IgG-Subclass, IgA and IgM Reactivities in African and European HIV-Infected Individuals with an HIV-1 Clade C Proteome-Based Array
por: Gallerano, Daniela, et al.
Publicado: (2015)

Betamethasone prevents human rhinovirus- and cigarette smoke- induced loss of respiratory epithelial barrier function
por: Waltl, Eva E., et al.
Publicado: (2018)

Usefulness of recombinant γ-gliadin 1 for identifying patients with celiac disease and monitoring adherence to a gluten-free diet
por: Srinivasan, Bharani, et al.
Publicado: (2015)

Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection
por: Cornelius, Carolin, et al.
Publicado: (2016)

Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs
por: Pfaar, O., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_425ejejk12h3lvs9j32vkjnbqg